FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007997046> ?p ?o ?g. }

• W2007997046 endingPage "369" @default.
• W2007997046 startingPage "360" @default.
• W2007997046 abstract "Selective cyclooxygenase inhibitors may retard the progression of cancer, but they have enhanced thrombotic potential. We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer.All serious adverse events that were cardiovascular thrombotic events were reviewed in 2434 patients with stage II or III colorectal cancer participating in a randomized, placebo-controlled trial of rofecoxib, 25 mg daily, started after potentially curative tumor resection and chemotherapy or radiotherapy as indicated. The trial was terminated prematurely owing to worldwide withdrawal of rofecoxib. To examine possible persistent risks, we examined cardiovascular thrombotic events reported up to 24 months after the trial was closed.The median duration of active treatment was 7.4 months. The 1167 patients receiving rofecoxib and the 1160 patients receiving placebo were well matched, with a median follow-up period of 33.0 months (interquartile range, 27.6 to 40.1) and 33.4 months (27.7 to 40.4), respectively. Of the 23 confirmed cardiovascular thrombotic events, 16 occurred in the rofecoxib group during or within 14 days after the treatment period, with an estimated relative risk of 2.66 (from the Cox proportional-hazards model; 95% confidence interval [CI], 1.03 to 6.86; P=0.04). Analysis of the Antiplatelet Trialists' Collaboration end point (the combined incidence of death from cardiovascular, hemorrhagic, and unknown causes; of nonfatal myocardial infarction; and of nonfatal ischemic and hemorrhagic stroke) gave an unadjusted relative risk of 1.60 (95% CI, 0.57 to 4.51; P=0.37). Fourteen more cardiovascular thrombotic events, six in the rofecoxib group, were reported within the 2 years after trial closure, with an overall unadjusted relative risk of 1.50 (95% CI, 0.76 to 2.94; P=0.24). Four patients in the rofecoxib group and two in the placebo group died from thrombotic causes during or within 14 days after the treatment period, and during the follow-up period, one patient in the rofecoxib group and five patients in the placebo group died from cardiovascular causes.Rofecoxib therapy was associated with an increased frequency of adverse cardiovascular events among patients with a median study treatment of 7.4 months' duration. (Current Controlled Trials number, ISRCTN98278138 [controlled-trials.com].)." @default.
• W2007997046 created "2016-06-24" @default.
• W2007997046 creator A5000481919 @default.
• W2007997046 creator A5028850629 @default.
• W2007997046 creator A5031393441 @default.
• W2007997046 creator A5040239879 @default.
• W2007997046 creator A5041416682 @default.
• W2007997046 creator A5043753160 @default.
• W2007997046 creator A5058468142 @default.
• W2007997046 creator A5062679128 @default.
• W2007997046 creator A5075524753 @default.
• W2007997046 creator A5084536457 @default.
• W2007997046 creator A5089210514 @default.
• W2007997046 date "2007-07-26" @default.
• W2007997046 modified "2023-09-26" @default.
• W2007997046 title "Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer" @default.
• W2007997046 cites W1973378060 @default.
• W2007997046 cites W1976739913 @default.
• W2007997046 cites W2011560877 @default.
• W2007997046 cites W2012920835 @default.
• W2007997046 cites W2018501386 @default.
• W2007997046 cites W2044750065 @default.
• W2007997046 cites W2051279880 @default.
• W2007997046 cites W2063252400 @default.
• W2007997046 cites W2067621583 @default.
• W2007997046 cites W2077991158 @default.
• W2007997046 cites W2081761148 @default.
• W2007997046 cites W2100631748 @default.
• W2007997046 cites W2148327508 @default.
• W2007997046 cites W2158131645 @default.
• W2007997046 cites W2158968701 @default.
• W2007997046 cites W2172116130 @default.
• W2007997046 cites W2225065195 @default.
• W2007997046 cites W4229722466 @default.
• W2007997046 cites W4239471829 @default.
• W2007997046 doi "https://doi.org/10.1056/nejmoa071841" @default.
• W2007997046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17652651" @default.
• W2007997046 hasPublicationYear "2007" @default.
• W2007997046 type Work @default.
• W2007997046 sameAs 2007997046 @default.
• W2007997046 citedByCount "120" @default.
• W2007997046 countsByYear W20079970462012 @default.
• W2007997046 countsByYear W20079970462013 @default.
• W2007997046 countsByYear W20079970462014 @default.
• W2007997046 countsByYear W20079970462015 @default.
• W2007997046 countsByYear W20079970462016 @default.
• W2007997046 countsByYear W20079970462017 @default.
• W2007997046 countsByYear W20079970462018 @default.
• W2007997046 countsByYear W20079970462019 @default.
• W2007997046 countsByYear W20079970462021 @default.
• W2007997046 countsByYear W20079970462022 @default.
• W2007997046 countsByYear W20079970462023 @default.
• W2007997046 crossrefType "journal-article" @default.
• W2007997046 hasAuthorship W2007997046A5000481919 @default.
• W2007997046 hasAuthorship W2007997046A5028850629 @default.
• W2007997046 hasAuthorship W2007997046A5031393441 @default.
• W2007997046 hasAuthorship W2007997046A5040239879 @default.
• W2007997046 hasAuthorship W2007997046A5041416682 @default.
• W2007997046 hasAuthorship W2007997046A5043753160 @default.
• W2007997046 hasAuthorship W2007997046A5058468142 @default.
• W2007997046 hasAuthorship W2007997046A5062679128 @default.
• W2007997046 hasAuthorship W2007997046A5075524753 @default.
• W2007997046 hasAuthorship W2007997046A5084536457 @default.
• W2007997046 hasAuthorship W2007997046A5089210514 @default.
• W2007997046 hasBestOaLocation W20079970461 @default.
• W2007997046 hasConcept C119060515 @default.
• W2007997046 hasConcept C121608353 @default.
• W2007997046 hasConcept C126322002 @default.
• W2007997046 hasConcept C127413603 @default.
• W2007997046 hasConcept C141071460 @default.
• W2007997046 hasConcept C142724271 @default.
• W2007997046 hasConcept C181199279 @default.
• W2007997046 hasConcept C185592680 @default.
• W2007997046 hasConcept C197934379 @default.
• W2007997046 hasConcept C204787440 @default.
• W2007997046 hasConcept C207103383 @default.
• W2007997046 hasConcept C27081682 @default.
• W2007997046 hasConcept C2778582115 @default.
• W2007997046 hasConcept C2779689624 @default.
• W2007997046 hasConcept C2780645631 @default.
• W2007997046 hasConcept C44249647 @default.
• W2007997046 hasConcept C500558357 @default.
• W2007997046 hasConcept C526805850 @default.
• W2007997046 hasConcept C55493867 @default.
• W2007997046 hasConcept C71924100 @default.
• W2007997046 hasConcept C78519656 @default.
• W2007997046 hasConceptScore W2007997046C119060515 @default.
• W2007997046 hasConceptScore W2007997046C121608353 @default.
• W2007997046 hasConceptScore W2007997046C126322002 @default.
• W2007997046 hasConceptScore W2007997046C127413603 @default.
• W2007997046 hasConceptScore W2007997046C141071460 @default.
• W2007997046 hasConceptScore W2007997046C142724271 @default.
• W2007997046 hasConceptScore W2007997046C181199279 @default.
• W2007997046 hasConceptScore W2007997046C185592680 @default.
• W2007997046 hasConceptScore W2007997046C197934379 @default.
• W2007997046 hasConceptScore W2007997046C204787440 @default.
• W2007997046 hasConceptScore W2007997046C207103383 @default.
• W2007997046 hasConceptScore W2007997046C27081682 @default.

• next